Samsung Biologics says its fourth plant will begin operations by October — six months ahead of schedule.  Samsung Biologics announced plans for its so called ‘P4 Super Plant’ in August 2020. This week, the Korean contract development and manufacturing organization (CDMO) told stakeholders the first phase of biomanufacturing operations will begin in the coming months. “Samsung Biologics’ Plant 4 construction is expected to be partially operational by October 2022 to support 6 X 10 kL production capacity,” the firm said in…

CDMO Scorpion Biological Services has entered a planned development partnership to construct a biodefense and biomanufacturing facility in Manhattan, Kansas. Contract development manufacturing organization (CDMO) Scorpion has announced a development collaboration with a private developer, the state of Kansas, and university affiliates to build a biodefense-focused large molecule and biologics biomanufacturing plant. According to the CDMO, the 500,000 square-foot plant will service around 144,000 L of biomanufacturing capacity across 48 bioreactors, which is being designed for large molecule biologics production.…

Enzyvant says the construction of a regenerative medicine facility in Morrisville, North Carolina will bolster its size, flexibility, and capability to support its commercial needs. Financial details of the expansion remain under wraps, but regenerative medicine focused firm Enzyvant says the development of a 25,972 square-foot facility will begin this summer and take around two and a half years to complete. The plant is located within the Research Triangle Park area and is being co-developed by and operated with Sumitomo…